Health Care & Life Sciences » Pharmaceuticals | Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc. | Mutual Funds

Mutual Funds that own Collegium Pharmaceutical Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Catalyst Eventide Gilead Fund
1,344,376
4.05%
0
1.24%
06/29/2018
Janus Global Life Sciences Fund
1,161,614
3.5%
-7,269
0.49%
06/30/2018
Janus Contrarian Fund
957,067
2.88%
0
0.59%
06/30/2018
Eventide Healthcare & Life Sciences Fund
863,234
2.6%
0
2.13%
06/29/2018
Vanguard Total Stock Market Index Fund
716,351
2.16%
0
0%
07/31/2018
Fidelity OTC Portfolio
659,300
1.99%
0
0.05%
07/31/2018
iShares Russell 2000 ETF
614,307
1.85%
-327
0.02%
09/06/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
591,836
1.78%
-23,900
0.44%
06/30/2018
Janus Capital Funds Plc - Global Life Sciences Fund
584,468
1.76%
584,468
0.39%
12/31/2017
Franklin Biotechnology Discovery Fund
394,150
1.19%
0
0.46%
03/31/2018

About Collegium Pharmaceutical

View Profile
Address
100 Technology Center Drive
Stoughton Massachusetts 02072
United States
Employees -
Website http://www.collegiumpharma.com
Updated 07/08/2019
Collegium Pharmaceutical, Inc. engages in the development and commercialization of next-generation, abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER, and ONSOLIS. Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.